DMT for Health & Longevity - Quick Reference Sheet

DMT for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

DMT, a fast-acting psychedelic also taken as the plant brew ayahuasca, is studied for depression. One supported session gave a quick, sometimes lasting mood lift in small placebo-compared trials. Evidence for other benefits is weaker; longevity claims rest on animal or cell studies. Main risks are brief blood pressure surges, vomiting, and intense fear; rarer serious harms cluster in psychotic or bipolar histories, risky drug combinations, and unsupervised use. (Full Review)

Protocol

Intravenous DMT fumarate (Imperial College London / Small Pharma)
21.5 mg over 10 minutes
Infused with psychological support; an optional second dose after two weeks added no further benefit
Inhaled DMT (Federal University of Rio Grande do Norte, Brazil)
15 mg, then 60 mg
Vaporized doses in one session, with clinical support
Ceremonial ayahuasca
About 1 mL/kg of brew
Roughly 0.36 mg/kg DMT in the Brazilian trial; churches and retreats use variable, healer-guided doses
Time to effect
Mood changes
Within one day
Usually clear by one week
Persistence
Up to three months
After one session; trials tracked persistence for three to twelve months
Lower Systemic Inflammation
Within 48 hours
C-reactive protein fell after ayahuasca, but not placebo

Benefits

Contraindications
  • Personal history of schizophrenia, other psychotic disorders, bipolar I or II disorder, or mania, or a first-degree relative with these conditions
  • Uncontrolled hypertension (resting blood pressure ≥140/90 mmHg), recent heart attack or stroke (<6 months), known aneurysm, significant arrhythmia, QTc >450 ms, or heart failure (NYHA Class III–IV)
  • Seizure disorders
  • Pregnancy or breastfeeding
  • Active suicidal intent or recent suicide attempt (<12 months) without close clinical supervision
  • Anyone under 18
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide, linezolid)
  • Lithium
  • SSRIs and SNRIs (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine) with ayahuasca
  • Other serotonergic drugs (tramadol, meperidine, methadone, tricyclic antidepressants such as clomipramine) with ayahuasca
  • Dextromethorphan (cough suppressants) with ayahuasca
  • St. John's wort, 5-HTP, L-tryptophan, SAMe with ayahuasca
  • Syrian rue (Peganum harmala) and passionflower in combination
Key Interactions
  • SSRIs and SNRIs (sertraline, venlafaxine), other serotonergic drugs (tramadol, tricyclic antidepressants), St. John's wort, 5-HTP, L-tryptophan, SAMe with pure DMT
  • CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) with ayahuasca
  • Stimulants (amphetamine, methylphenidate)
  • Antipsychotics (haloperidol, risperidone, quetiapine)
  • Pindolol
  • Decongestants (pseudoephedrine, phenylephrine)
  • Antihistamines with serotonergic activity (chlorpheniramine) with ayahuasca
  • Yohimbe and high-dose caffeine
  • Cannabis
  • Alcohol
  • Tobacco (including ceremonial mapacho)
  • Tyramine-rich foods (aged cheese, cured meats, soy sauce) with ayahuasca

Risk & Side Effects

  • High: Transient Rises in Blood Pressure and Heart Rate; Nausea and Vomiting; Acute Anxiety and Distressing Experiences
  • Medium: Administration-Site Discomfort; Headache and Dizziness; Lingering Psychological Difficulties After Use
  • Low: Psychosis and Mania in Vulnerable People; Serotonin Toxicity With Serotonergic Drugs; Serious Medical Events Reported to Poison Centers; Seizures When Combined With Lithium; Persistent Visual Disturbances
  • Speculative: Heart Valve Damage With Frequent Dosing; Harm During Pregnancy; Brain Structural Changes With Heavy Long-Term Use

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Acute surge risk
Resting heart rate 50–70 bpm Acute surge risk
QTc on electrocardiogram <430 ms (men), <450 ms (women) Rhythm safety
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L Inflammation trend
PHQ-9 depression score 0–4 Track mood response
C-SSRS suicide screen No ideation or behavior Safety check

Cadence: Vital signs before dosing and every 5–15 minutes until effects resolve; symptom questionnaires at 1 day, 1 week, 2 weeks, 1 month, and 3 months; optional hs-CRP repeated at 1 and 3 months

Qualitative Assessment

  • Mood, hopefulness, and emotional flexibility
  • Sleep quality in the week after dosing
  • Cravings and alcohol or drug use
  • Anxiety, intrusive thoughts, or unusual perceptions